低疾病活动状态/缓解预测系统性红斑狼疮患者更好的健康相关生活质量:秘鲁Almenara狼疮队列数据
该研究纳入243例系统性红斑狼疮患者,每6个月随访,使用LupusQoL问卷评估健康相关生活质量。随访中61.6%的访视被归类为LDAS/缓解。广义估计方程分析显示,LDAS/缓解可预测后续访视中身体健康、疼痛、计划、对他人的负担、情绪健康和疲劳等维度的HRQoL改善。
要点
- LDAS/缓解与身体健康、疼痛、计划、负担、情绪健康和疲劳维度HRQoL改善相关。
- 研究采用广义估计方程分析,调整了潜在混杂因素。
- LDAS定义为SLEDAI-2K≤4且泼尼松≤7.5 mg/天且免疫抑制剂维持治疗。
核心结论
- 处于LDAS/缓解可预测系统性红斑狼疮患者更好的健康相关生活质量,尤其在身体健康、疼痛、计划、对他人的负担、情绪健康和疲劳维度。
研究设计与样本
- 单中心系统性红斑狼疮患者队列,纳入至少完成2次访视者,每6个月随访,使用LupusQoL问卷评估HRQoL。
- 采用广义估计方程分析,以随后访视的LupusQoL 8个成分之一为结局,以前次访视的活动状态为预测变量,并调整潜在混杂因素。
主要发现
- 共纳入243例患者,随访期间590次访视(61.6%)被归类为LDAS/缓解。
- LDAS/缓解预测身体健康维度HRQoL改善(B=4.17,95%CI 1.20-7.14,P=0.006)。
- LDAS/缓解预测疼痛维度改善(B=6.47,95%CI 3.18-9.76,P<0.001)。
- LDAS/缓解预测计划维度改善(B=4.97,95%CI 1.43-8.52,P=0.006)。
- LDAS/缓解预测对他人的负担维度改善(B=4.12,95%CI 0.24-8.01,P=0.037)。
关键数值与推荐
- 缓解定义为SLEDAI-2K评分为0、泼尼松每日剂量≤5 mg/天且免疫抑制剂维持剂量。
- LDAS定义为SLEDAI-2K评分≤4、泼尼松每日剂量≤7.5 mg/天且免疫抑制剂维持治疗。
- 分析时将缓解与LDAS合并为一个变量。
临床怎么用
- 在临床中,达到LDAS/缓解可作为改善SLE患者健康相关生活质量的治疗目标之一。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine if low disease activity state (LDAS)/remission predicts a better health-related quality of life (HRQoL). METHODS: Patients with systemic lupus erythematosus from a single center and having completed at least 2 visits were included. Visits were performed every 6 months. HRQoL was measured with the LupusQoL questionnaire. The definition of remission included a Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of 0, prednisone daily dosage of ≤5 mg/day, and immunosuppressive drugs on maintenance dose. LDAS was defined as a SLEDAI-2K score of ≤4, prednisone daily dosage of ≤7.5 mg/day, and immunosuppressive drugs as maintenance therapy. For these analyses, remission and LDAS were combined as one variable. Generalized estimating equations were calculated, using as the outcome 1 of each of the 8 components of the LupusQoL questionnaire in the subsequent visit and the activity state in the previous visit. Multivariable models were adjusted for possible confounders. RESULTS: A total of 243 patients were included. During the follow-up, 590 visits (61.6%) were categorized as LDAS/remission. LDAS/remission predicted a better HRQoL in the components of physical health (B = 4.17 [95% confidence interval (95% CI) 1.20, 7.14]; P = 0.006), pain (B = 6.47 [95% CI 3.18, 9.76]; P < 0.001), planning (B = 4.97 [95% CI 1.43, 8.52]; P = 0.006), burden to others (B = 4.12 [95% CI 0.24, 8.01]; P = 0.037], emotional health (B = 4.50 [95% CI 1.56, 7.44]; P = 0.003), and fatigue (B = 3.25 [95% CI 0.04, 6.47]; P = 0.048). CONCLUSION: Being in LDAS/remission predicts a better HRQoL, especially in the components of physical health, pain, planning, burden to others, emotional health, and fatigue.
引用
- Ugarte-Gil MF, Gamboa-Cárdenas RV, Reátegui-Sokolova C, et al. Better Health-Related Quality of Life in Systemic Lupus Erythematosus Predicted by Low Disease Activity State/Remission: Data From the Peruvian Almenara Lupus Cohort. Arthritis Care Res (Hoboken). 2020. PMID: 31199590. doi:10.1002/acr.24009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。